[Translation] A Phase I clinical study to evaluate the safety/tolerability and pharmacokinetics/pharmacodynamics of the BTK protein degrader HZ-Q1070 in the treatment of relapsed or refractory B-cell malignancies
Main purposes: 1) Evaluate the safety/tolerability of HZ-Q1070 in patients with relapsed or refractory B-cell malignancies; 2) Determine the maximum tolerated dose (MTD) and phase II clinical recommended dose (RP2D) of HZ-Q1070 ). Secondary objectives: 1) Evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of HZ-Q1070 in patients with relapsed or refractory B-cell malignancies; 2) Preliminarily evaluate the efficacy of HZ-Q1070 in relapsed or effectiveness in patients with refractory B-cell malignancies.
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.